Catalent, Inc. is engaged in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. The Company’s Biologics segment provides formulation, development, and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells (iPSCs); oncolytic viruses, and vaccines. It also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges, and analytical development and testing services for large molecules. The Company’s Pharma and Consumer Health segment comprises capabilities for oral solid doses forms, softgels, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms. It also provides formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms, and clinical trial development and supply services.

• Revenue in USD (TTM)4.42bn
• Net income in USD-413.00m
• Incorporated2007
• Employees16.90k

• Location
  Catalent Inc14 Schoolhouse RdSOMERSET 08873-1213United StatesUSA
• Phone+1 (732) 537-6200
• Fax+1 (732) 537-6480
• Websitehttps://www.catalent.com/